Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Why Roku, GGP, and Nektar Therapeutics Jumped Today


Why Roku, GGP, and Nektar Therapeutics Jumped Today

The stock market got off to a solid start on Monday, bouncing back from small losses early in the trading day to finish with modest gains. Major benchmarks were up less than a quarter percent as market participants kept their eyes on the slowing trickle of third-quarter earnings reports as well as the negotiations related to tax reform in Washington. Some individual stocks logged significant gains. Roku (NASDAQ: ROKU), GGP (NYSE: GGP), and Nektar Therapeutics (NASDAQ: NKTR) were among the best performers on the day. Below, we'll look more closely at these stocks to tell you why they did so well.

Shares of Roku continued their upward surge from last week, surging nearly 30% to post the stock's third big daily gain in a row as excitement keeps building about the streaming media player manufacturer's prospects. Strong earnings results from Roku ignited the upward move for the stock late last week, and those following the company have marveled at the pace at which CEO Anthony Wood has joined the ranks of technology billionaires. If Roku continues to gain adoption among manufacturers of televisions and other hardware and can keep its advertisers happy, then there's every reason to think that the company can support a healthy share-price valuation.

Image source: Roku.

Continue reading


Source: Fool.com

Nektar Therapeutics Aktie

1,25 €
3,71 %
Ein erheblicher Kursanstieg bei Nektar Therapeutics heute, um 3,71 %.
Nektar Therapeutics sticht etwas positiv hervor mit 4 Buy- und 1 Sell-Einschätzungen.
Das Kursziel von 2 € für Nektar Therapeutics bedeutet eine deutliche Steigerung von über 50% gegenüber dem aktuellen Kurs von 1.25 €.
Like: 0
Teilen

Kommentare